Login
OnKure Therapeutics, Inc. logo

OnKure Therapeutics, Inc.

onkuretherapeutics.com

What Do They Do?

Develops small-molecule medicines designed to target mutations driving cancers and vascular malformations, for patients with those diseases.

How Do They Make Money?

FY2025 revenue

Do Revenues Turn Into Profits?

No. It lost $59.5M in FY2025.

Operating income, FY2025
−1834% of revenue
▼ −16% (Loss) vs FY2024 (−$54.4M)
Net income, FY2025
−1734% of revenue
▼ −13% (Loss) vs FY2024 (−$52.7M)
Free cash flow, FY2025
−1511% of revenue
▼ −1% (Loss) vs FY2024 (−$51.2M)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −21% (Loss)
vs −$14.7M in Q3 FY2025

From mitochondrial disease to targeted drugs The older report centered on mavodelpar for rare genetic mitochondrial diseases; the latest centers on mutation-targeted drugs for breast cancer and includes a vascular-malformations program.

Who Do They Compete With?

Competes with Novartis, Astra Zeneca, Celcuity, Menarini, Totus Medicines, Relay Therapeutics, Scorpion Therapeutics, and Synnovation Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support